Back to search results

Pharmacologic Therapies to Mitigate Radiation-Associated Heart Disease

This study is looking for ways to prevent heart problems that can happen after radiation therapy for chest cancers like breast, lung, esophageal, and mediastinal cancers. Radiation can sometimes affect the heart, leading to a condition called radiation-induced heart disease (RIHD). Currently, there isn't a standard medication to prevent this. This study will test if two common medications, Atorvastatin (a statin) and Lisinopril (an ACE inhibitor), can reduce the impact of radiation on your heart. Some participants will receive these medications, while others will receive a placebo (an inactive substance). Researchers will measure changes in your heart's blood flow before and six months after radiation therapy to see if the medications help. Adults aged 18 and older who are receiving radiation for these chest cancers may be able to join. The current recruitment status is unclear.

Study design
This study plans to enroll 60 participants and will compare the effects of active medications (Atorvastatin and Lisinopril) against a placebo.
What's involved
You will need to provide written informed consent, agree to serial blood draws, and consent to the use of biological specimens.
Compensation
Not stated in the trial record.
Follow-up
Your heart's blood flow will be measured six months after radiation therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07685938

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Recruiting
PHASE2Ages 18+InterventionalSupportive care
UNC Lineberger Comprehensive Cancer Center
~60 participants
Updated 2026-09-17 on ClinicalTrials.gov
What's tested:Atorvastatin and LisinoprilPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent difference in the radiation (RT)-induced reduction of myocardial perfusion
Measured over Pre radiation therapy and 6-month post radiation therapy

Conditions

Chest Wall Tumor
Breast Cancer
Lung Cancer
Esophageal Cancer
Mediastinal Cancers
Spine Metastases
Spinal Tumor
Thoracic Cancer
Thoracic Neoplasms

Explore related trials

Breast CarcinomaEsophageal CarcinomaLung Non-Small Cell CarcinomaMalignant Mediastinal NeoplasmMetastatic Malignant Neoplasm in the SpineSolid Neoplasm

NCT07685938

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill

    Chapel Hill, North Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Shivani Sud, MD · PRINCIPAL_INVESTIGATOR · UNC Lineberger Comprehensive Cancer Center

Who to contact

Claire Kowalczyk
[email protected]
984-974-0000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent obtained to participate in the study and HIPAA
authorization for release of personal health information.
Subjects is willing and able to comply with study procedures based on the
judgement of the investigator.
Consent for serial blood draws and consent for use of biological specimens.
Age ≥ 18 years at the time of consent

Exclusion

Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Pre-existing use of a statin or ACE-inhibitor
Pre-existing hypotension

What this trial measures

  • Percent difference in the radiation (RT)-induced reduction of myocardial perfusionPre radiation therapy and 6-month post radiation therapy

    Percent difference in the radiation (RT)-induced reduction of myocardial perfusion in cardiac regions receiving ≥25Gy equivalent dose in 2Gy fractions (EQD2) based on comparison of before and after RT among participants receiving placebo and statins and angiotensin-converting enzyme (ACE) inhibitors intervention.